Bristol-Myers Squibb Company (BMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 11,892,000 | 12,201,000 | 11,865,000 | 11,477,000 | 10,966,000 |
| Cost of Goods | 2,957,000 | 3,267,000 | 2,932,000 | 2,745,000 | 2,506,000 |
| Gross Profit | 8,935,000 | 8,934,000 | 8,933,000 | 8,732,000 | 8,460,000 |
| Operating Expenses | 7,259,000 | 7,648,000 | 20,449,000 | 7,058,000 | 6,323,000 |
| Operating Income | 1,676,000 | 1,286,000 | -11,516,000 | 1,674,000 | 2,137,000 |
| Pre-tax Income | 1,676,000 | 1,286,000 | -11,516,000 | 1,674,000 | 2,137,000 |
| Income Tax | 461,000 | -398,000 | 392,000 | -88,000 | 203,000 |
| Net Income Continuous | 1,215,000 | 1,684,000 | -11,908,000 | 1,762,000 | 1,934,000 |
| Minority Interests | 4,000 | 4,000 | 3,000 | N/A | 6,000 |
| Net Income | $1,211,000 | $1,680,000 | $-11,911,000 | $1,762,000 | $1,928,000 |
| EPS Basic Total Ops | 0.60 | 0.83 | -5.89 | 0.87 | 0.94 |
| EPS Basic Continuous Ops | 0.60 | 0.83 | -5.89 | 0.87 | 0.94 |
| EPS Diluted Total Ops | 0.60 | 0.83 | -5.89 | 0.87 | 0.93 |
| EPS Diluted Continuous Ops | 0.60 | 0.83 | -5.89 | 0.87 | 0.94 |
| EPS Diluted Before Non-Recurring Items | 1.80 | 2.07 | -4.40 | 1.70 | 2.00 |
| EBITDA(a) | $4,268,000 | $3,882,000 | $-8,984,000 | $4,138,000 | $4,572,000 |